Literature DB >> 22919240

Colorectal cancer in patients with inflammatory bowel disease: can we predict risk?

Vibeke Andersen1, Jonas Halfvarson, Ulla Vogel.   

Abstract

The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), may be complicated by colorectal cancer (CRC). In a recent population-based cohort study of 47 347 Danish patients with IBD by Tine Jess and colleagues 268 patients with UC and 70 patients with CD developed CRC during 30 years of observation. The overall risk of CRC among patients with UC and CD was comparable with that of the general population. However, patients diagnosed with UC during childhood or as adolescents, patients with long duration of disease and those with concomitant primary sclerosing cholangitis were at increased risk. In this commentary, we discuss the mechanisms underlying carcinogenesis in IBD and current investigations of genetic susceptibility in IBD patients. Further advances will depend on the cooperative work by epidemiologist and molecular geneticists in order to identify genetic polymorphisms involved in IBD-associated CRC. The ultimate goal is to incorporate genotypes and clinical parameters into a predictive model that will refine the prediction of risk for CRC in colonic IBD. The challenge will be to translate these new findings into clinical practice and to determine appropriate preventive strategies in order to avoid CRC in IBD patients. The achieved knowledge may also be relevant for other inflammation-associated cancers.

Entities:  

Keywords:  Colorectal cancer; Crohn’s disease; Genetics; Inflammation-associated cancer; Inflammatory bowel disease; Preventive strategies; Ulcerative colitis

Mesh:

Year:  2012        PMID: 22919240      PMCID: PMC3422788          DOI: 10.3748/wjg.v18.i31.4091

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  The Role of Inflammation in the Pathogenesis of Colorectal Cancer.

Authors:  Beth B McConnell; Vincent W Yang
Journal:  Curr Colorectal Cancer Rep       Date:  2009-04-01

2.  Assessment of the diagnoses of Crohn's disease and ulcerative colitis in a Danish hospital information system.

Authors:  K Fonager; H T Sørensen; S N Rasmussen; J Møller-Petersen; M Vyberg
Journal:  Scand J Gastroenterol       Date:  1996-02       Impact factor: 2.423

3.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.

Authors:  Annette J Vangsted; Tobias W Klausen; Niels Abildgaard; Niels F Andersen; Peter Gimsing; Henrik Gregersen; Bjørn A Nexø; Ulla Vogel
Journal:  Ann Hematol       Date:  2011-02-24       Impact factor: 3.673

5.  Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study.

Authors:  J Askling; P W Dickman; P Karlén; O Broström; A Lapidus; R Löfberg; A Ekbom
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

6.  p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis.

Authors:  Ramanarao Dirisina; Rebecca B Katzman; Tatiana Goretsky; Elizabeth Managlia; Navdha Mittal; David B Williams; Wei Qiu; Jian Yu; Navdeep S Chandel; Lin Zhang; Terrence A Barrett
Journal:  Gastroenterology       Date:  2011-05-27       Impact factor: 22.682

7.  Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years.

Authors:  Tine Jess; Jacob Simonsen; Kristian Tore Jørgensen; Bo Vestergaard Pedersen; Nete Munk Nielsen; Morten Frisch
Journal:  Gastroenterology       Date:  2012-04-19       Impact factor: 22.682

8.  Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

Authors:  Matthew D Rutter; Brian P Saunders; Kay H Wilkinson; Steve Rumbles; Gillian Schofield; Michael A Kamm; Christopher B Williams; Ashley B Price; Ian C Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

Review 9.  Promise and pitfalls of the Immunochip.

Authors:  Adrian Cortes; Matthew A Brown
Journal:  Arthritis Res Ther       Date:  2011-02-01       Impact factor: 5.156

10.  Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis.

Authors:  Josep Bassaganya-Riera; Monica Viladomiu; Mireia Pedragosa; Claudio De Simone; Adria Carbo; Rustem Shaykhutdinov; Christian Jobin; Janelle C Arthur; Benjamin A Corl; Hans Vogel; Martin Storr; Raquel Hontecillas
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.752

View more
  7 in total

Review 1.  Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review.

Authors:  Ammar Hassanzadeh Keshteli; Vickie E Baracos; Karen L Madsen
Journal:  World J Gastroenterol       Date:  2015-01-28       Impact factor: 5.742

2.  Colonoscopy is associated with a reduced risk for colon cancer and mortality in patients with inflammatory bowel diseases.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-17       Impact factor: 11.382

3.  Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases.

Authors:  Ashwin N Ananthakrishnan; Su-Chun Cheng; Tianxi Cai; Andrew Cagan; Vivian S Gainer; Peter Szolovits; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Isaac Kohane; Katherine P Liao
Journal:  Clin Gastroenterol Hepatol       Date:  2014-01-07       Impact factor: 11.382

4.  Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Susanne Churchill; Elizabeth W Karlson; Shawn N Murphy; Katherine P Liao; Isaac Kohane
Journal:  Clin Gastroenterol Hepatol       Date:  2016-02-22       Impact factor: 11.382

5.  Panax notoginseng attenuates experimental colitis in the azoxymethane/dextran sulfate sodium mouse model.

Authors:  Xiao-Dong Wen; Chong-Zhi Wang; Chunhao Yu; Lei Zhao; Zhiyu Zhang; Adiba Matin; Yunwei Wang; Ping Li; Shu-Yuan Xiao; Wei Du; Tong-Chuan He; Chun-Su Yuan
Journal:  Phytother Res       Date:  2013-10-21       Impact factor: 5.878

6.  Whole-Exome Sequencing Analyses of Inflammatory Bowel Disease-Associated Colorectal Cancers.

Authors:  Ana I Robles; Giovanni Traverso; Ming Zhang; Nicholas J Roberts; Mohammed A Khan; Christine Joseph; Gregory Y Lauwers; Florin M Selaru; Maria Popoli; Meredith E Pittman; Xiquan Ke; Ralph H Hruban; Stephen J Meltzer; Kenneth W Kinzler; Bert Vogelstein; Curtis C Harris; Nickolas Papadopoulos
Journal:  Gastroenterology       Date:  2016-01-05       Impact factor: 22.682

Review 7.  Intestinal microbiota, probiotics and human gastrointestinal cancers.

Authors:  Antonella Orlando; Francesco Russo
Journal:  J Gastrointest Cancer       Date:  2013-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.